248 related articles for article (PubMed ID: 22331604)
1. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.
Naggie S; Osinusi A; Katsounas A; Lempicki R; Herrmann E; Thompson AJ; Clark PJ; Patel K; Muir AJ; McHutchison JG; Schlaak JF; Trippler M; Shivakumar B; Masur H; Polis MA; Kottilil S
Hepatology; 2012 Aug; 56(2):444-54. PubMed ID: 22331604
[TBL] [Abstract][Full Text] [Related]
2. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
3. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.
de Araujo ES; Dahari H; Cotler SJ; Layden TJ; Neumann AU; Melo CE; Barone AA
J Acquir Immune Defic Syndr; 2011 Feb; 56(2):95-9. PubMed ID: 21157362
[TBL] [Abstract][Full Text] [Related]
5. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
[TBL] [Abstract][Full Text] [Related]
6. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
[TBL] [Abstract][Full Text] [Related]
7. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
8. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
9. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM
AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939
[TBL] [Abstract][Full Text] [Related]
10. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Asahina Y; Tsuchiya K; Muraoka M; Tanaka K; Suzuki Y; Tamaki N; Hoshioka Y; Yasui Y; Katoh T; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nitta S; Sakamoto N; Izumi N
Hepatology; 2012 Jan; 55(1):20-9. PubMed ID: 21898478
[TBL] [Abstract][Full Text] [Related]
11. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O
Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
[TBL] [Abstract][Full Text] [Related]
13. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.
McCarthy JJ; Li JH; Thompson A; Suchindran S; Lao XQ; Patel K; Tillmann HL; Muir AJ; McHutchison JG
Gastroenterology; 2010 Jun; 138(7):2307-14. PubMed ID: 20176026
[TBL] [Abstract][Full Text] [Related]
14. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene.
Grandi T; da Silva CM; Amaral KM; Picon PD; Costi C; da Fré NN; Fiegenbaum M; Niel C; Rossetti ML
Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):48-53. PubMed ID: 23440114
[TBL] [Abstract][Full Text] [Related]
15. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
16. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Lange CM; Moradpour D; Doehring A; Lehr HA; Müllhaupt B; Bibert S; Bochud PY; Antonino AT; Pascual M; Farnik H; Shi Y; Bechstein WO; Moench C; Hansmann ML; Sarrazin C; Lötsch J; Zeuzem S; Hofmann WP
J Hepatol; 2011 Aug; 55(2):322-7. PubMed ID: 21147186
[TBL] [Abstract][Full Text] [Related]
17. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
Rallón NI; Naggie S; Benito JM; Medrano J; Restrepo C; Goldstein D; Shianna KV; Vispo E; Thompson A; McHutchison J; Soriano V
AIDS; 2010 May; 24(8):F23-9. PubMed ID: 20389235
[TBL] [Abstract][Full Text] [Related]
18. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Osinusi A; Bon D; Nelson A; Lee YJ; Poonia S; Shivakumar B; Cai SY; Wood B; Haagmans B; Lempicki R; Herrmann E; Sneller M; Polis M; Masur H; Kottilil S
J Med Virol; 2014 Feb; 86(2):177-85. PubMed ID: 24166150
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
Pineda JA; Caruz A; Rivero A; Neukam K; Salas I; Camacho A; Palomares JC; Mira JA; Martínez A; Roldán C; de la Torre J; Macías J
Clin Infect Dis; 2010 Oct; 51(7):788-95. PubMed ID: 20804372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
